Renewed Gulf tensions increase demand for dollar safe haven, USD/JPY reaches the key 160 level
- On Wednesday, the US dollar continued to strengthen, pushing the USD/JPY exchange rate down to the closely watched 160 level. Renewed escalation of conflicts in the Gulf region boosted investors' demand for the safe-haven US dollar.
- The US Central Command stated that Iran fired ballistic missiles at neighboring countries, but none hit their targets; the US military subsequently launched strikes on Qeshm Island in response to Tehran’s attempted attacks. This round of military action comes as diplomatic negotiations between the US and Iran remain stalled, with market sentiment subdued and the US dollar gaining the upper hand.
- During early Asian trading, the US dollar once touched 160 yen against the Japanese yen. Previously, Japanese authorities had intervened in the forex market near this level. This erased gains achieved a month earlier when Tokyo spent about 11.7 trillion yen (approximately 73.14 billion US dollars) to intervene in the foreign exchange market. The latest quote for USD/JPY stands at 159.89, nearly flat.
- Hirofumi Suzuki, chief forex strategist at Sumitomo Mitsui Banking Corporation, stated that upward pressure on crude oil prices is making the yen more vulnerable to selling. He believes the so-called “defense line” may not be a precise point, but the 160-161 range is being closely watched, implying that Japanese authorities may take further intervention measures. Japan’s Minister of Finance, Shun’ichi Katayama, also said on Wednesday that authorities are prepared to take appropriate action in the foreign exchange market.
- The prolonged Middle East conflict and persistently high energy prices have led investors to increase their bets on major central banks tightening monetary policy this year, marking a sharp reversal from the prevailing expectations of rate cuts before the outbreak of the conflict. The US Dollar Index held steady at 99.21, up slightly overnight.
- In terms of economic data, Tuesday’s figures showed US job openings in April saw their largest increase in five years, though this surge may overstate the true health of the labor market. Private sector employment data will be released later on Wednesday, while the key nonfarm payrolls report is scheduled for Friday.
- Kristina Clifton, strategist at Commonwealth Bank of Australia, stated that the US labor market is improving after 2025’s weakness. Coupled with high inflation, it is expected that the Federal Reserve will begin a rate hike cycle in December 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nvidia pledges to invest $1 billion over the next five years to advance scientific development in the United States
Nvidia (NVDA.US) has pledged to invest $1 billion over the next five years to advance scientific development in the United States.
Updated Version 3 - Viatris Bets on the Non-Opioid Pain Medication Sector with a $1.65 Billion Acquisition of Pacira
Viatris has proposed an acquisition price of $36.50 per share, representing a 44.8% premium over Pacira’s last closing price. This acquisition will drive Viatris’ transition from the generic drug business to the field of patented pharmaceuticals. The company stated that the transaction is expected to be completed by the end of 2026 and will immediately enhance its financial metrics. On Thursday, Siddhi Mahatole from Reuters reported that pharmaceutical company Viatris (VTRS.O) announced a $1.65 billion cash acquisition of Pacira BioSciences (PCRX.O), aiming to add two non-opioid pain medications to its portfolio and expand beyond its core generic drugs into the high-value branded drug market. Viatris will acquire Pacira at $36.50 per share, a 44.8% premium over its last trading day closing price. In early trading, Pacira’s stock surged around 44%, while Viatris shares fell nearly 2%. Oppenheimer analyst Les Sulewski commented that the premium was “full price” and noted limited antitrust risk. He mentioned that Pacira has faced pressure from activist investors since November 2025, and with the stock close to the offer price, investors appear confident the deal will close with limited expectations for a higher bid. Through this transaction, Viatris will obtain Pacira’s “Exparel” (for the management of acute postsurgical pain) and “Zilretta” (for pain associated with osteoarthritis of the knee). In 2025, these two products are expected to achieve net sales of $575.1 million and $116.6 million respectively. Viatris stated it plans to promote these drugs in select international markets, seeking new growth drivers while deepening its presence in the patented drug segment. CEO Scott Smith said the acquisition “creates synergies with our fast-acting Meloxicam market opportunity and positions us as a leader in non-opioid pain therapeutics.” The US Food and Drug Administration is expected to decide by December 27 whether to approve Viatris’ rapid-acting Meloxicam for the treatment of moderate to severe acute pain. Viatris said it plans to mainly use excess cash to finance the acquisition, with the remainder raised through short-term borrowing. The company noted the deal will have a minimal impact on its overall leverage. Previously, Viatris raised its annual adjusted profit forecast in August thanks to strong branded drug sales and growth in the Chinese market. However, the company continues to face pressures from manufacturing setbacks in India, including a fire at its Nashik plant, as well as intense competition in the generics market. Both parties expect the deal to be completed by the end of 2026. Viatris said the acquisition will immediately improve its financial guidance metrics.
Crypto prices
More
